Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Stimulant dopaminergique And NotJ. Vaamonde

List of bibliographic references

Number of relevant bibliographic references: 112.
Ident.Authors (with country if any)Title
000083 Daniel Weintraub [États-Unis] ; Eugenia Mamikonyan [États-Unis] ; Kimberly Papay [États-Unis] ; Judith A. Shea [États-Unis] ; Sharon X. Xie [États-Unis] ; Andrew Siderowf [États-Unis]Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale
000214 Michele Poletti [Italie] ; Giulio Perugi [Italie] ; Chiara Logi [Italie] ; Anna Romano [Italie] ; Paolo Del Dotto [Italie] ; Roberto Ceravolo [Italie] ; Giuseppe Rossi [Italie] ; Pasquale Pepe [Italie] ; Liliana Dell'Osso [Italie] ; Ubaldo Bonuccelli [Italie]Dopamine Agonists and Delusional Jealousy in Parkinson's Disease: A Cross-Sectional Prevalence Study
000307 Roger Kurlan [États-Unis] ; Giovanna Crespi [États-Unis] ; Barbara Coffey [États-Unis] ; Kirsten Mueller-Vahl [Allemagne] ; Stephen Koval [États-Unis] ; Glen Wunderlich [Canada]A Multicenter Randomized Placebo-Controlled Clinical Trial of Pramipexole for Tourette's Syndrome
000351 Vibeke Guldbrand Rasmussen [Danemark] ; Karen Stergaard [Danemark] ; Erik Dupont [Danemark] ; Steen Hvitfeldt Poulsen [Danemark]The Risk of Valvular Regurgitation in Patients with Parkinson's Disease Treated with Dopamine Receptor Agonists
000361 Klaus Seppi ; Daniel Weintraub ; Miguel Coelho ; Santiago Perez-Lloret ; Susan H. Fox ; Regina Katzenschlager ; Eva-Maria Hametner ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Christopher G. Goetz ; Cristina SampaioThe Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Non-Motor Symptoms of Parkinson's Disease
000362 Susan H. Fox [Canada] ; Regina Katzenschlager [Autriche] ; Shen-Yang Lim [Malaisie] ; Bernard Ravina [États-Unis] ; Klaus Seppi [Autriche] ; Miguel Coelho [Portugal] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Christopher G. Goetz [États-Unis] ; Cristina Sampaio [Portugal]The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Motor Symptoms of Parkinson's Disease
000409 Claudia Trenkwalder [Allemagne] ; Bryan Kies [Afrique du Sud] ; Monika Rudzinska [Pologne] ; Jennifer Fine [Afrique du Sud] ; Janos Nikl [Hongrie] ; Krystyna Honczarenko [Pologne] ; Peter Dioszeghy [Hongrie] ; Dennis Hill [États-Unis] ; Tim Anderson [Nouvelle-Zélande] ; Vilho Myllyla [Finlande] ; Jan Kassubek [Allemagne] ; Malcolm Steiger [Royaume-Uni] ; Marco Zucconi [Italie] ; Eduardo Tolosa [Espagne] ; Werner Poewe [Autriche] ; Erwin Surmann [Allemagne] ; John Whitesides [États-Unis] ; Babak Boroojerdi [Allemagne] ; Kallol Ray Chaudhuri [Royaume-Uni]Rotigotine Effects on Early Morning Motor Function and Sleep in Parkinson's Disease: A Double-Blind, Randomized, Placebo-Controlled Study (RECOVER)
000457 Atbin Djamshidian [Royaume-Uni] ; Francisco Cardoso [Brésil] ; Donald Grosset [Royaume-Uni] ; Henrietta Bowden-Jones [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni]Pathological Gambling in Parkinson's Disease-A Review of the Literature
000468 Cristina Sampaio [Portugal] ; Juliana Bronzova [Pays-Bas] ; Robert A. Hauser [États-Unis] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Serge V. Van De Witte [Pays-Bas] ; Ad Theeuwes [Pays-Bas]Pardoprunox in Early Parkinson's Disease: Results from 2 Large, Randomized Double-Blind Trials
000512 Olivier Rascol [France] ; Andres Lozano [Canada] ; Matthew Stern [États-Unis] ; Werner Poewe [Autriche]Milestones in Parkinson's Disease Therapeutics
000555 Maria Milenkova [Allemagne, Bulgarie] ; Bahram Mohammadi [Allemagne] ; Katja Kollewe [Allemagne] ; Christoph Schrader [Allemagne] ; Anja Fellbrich [Allemagne] ; Matthias Wittfoth [Allemagne] ; Reinhard Dengler [Allemagne] ; Thomas F. Münte [Allemagne]Intertemporal Choice in Parkinson's Disease
000867 Sean S. O'Sullivan [Royaume-Uni] ; Andrew H. Evans [Australie] ; Niall P. Quinn [Royaume-Uni] ; Andrew D. Lawrence [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni]Reckless Generosity in Parkinson's Disease
000873 Robert A. Hauser [États-Unis] ; Anthony H. V. Schapira [Royaume-Uni] ; Olivier Rascol [France] ; Paolo Barone [Italie] ; Yoshikuni Mizuno [Japon] ; Laurence Salin [France] ; Monika Haaksma [Autriche] ; Nolwenn Juhel [France] ; Werner Poewe [Autriche]Randomized, Double-Blind, Multicenter Evaluation of Pramipexole Extended Release Once Daily in Early Parkinson's Disease
000928 Olivier Rascol [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France] ; Anne-Marie Bonnet [France] ; Christine Brefel-Courbon [France] ; Pierre Cesaro [France] ; Philippe Damier [France] ; Bérengère Debilly [France] ; Frank Durif [France] ; Monique Galitzky [France] ; Jean-Marie Grouin [France] ; Sylvie Pennaforte [France] ; Gabriel Villafane [France] ; Sadek Yaici [France] ; Yves Agid [France]Orodispersible Sublingual Piribedil to Abort OFF Episodes: A Single Dose Placebo-Controlled, Randomized, Double-Blind, Cross-Over Study
000A13 Sean S. O'Sullivan [Royaume-Uni] ; Atbin Djamshidian [Royaume-Uni, Autriche] ; Zeshan Ahmed [Royaume-Uni] ; Andrew H. Evans [Australie] ; Andrew D. Lawrence [Royaume-Uni] ; Janice L. Holton [Royaume-Uni] ; Tamas Revesz [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni]Impulsive-Compulsive Spectrum Behaviors in Pathologically Confirmed Progressive Supranuclear Palsy
000A30 Mario Coletti Moja [Italie]Hiccups Associated with Non-Ergoline Dopamine Agonists in Parkinson's Disease
000A86 Olivier Rascol [France] ; Paolo Barone [Italie] ; Robert A. Hauser [États-Unis] ; Yoshikuni Mizuno [Japon] ; Werner Poewe [Autriche] ; Anthony H. V. Schapira [Royaume-Uni] ; Laurence Salin [France] ; Mandy Sohr [Allemagne] ; Catherine Debieuvre [France]Efficacy, Safety, and Tolerability of Overnight Switching from Immediate- to Once Daily Extended-Release Pramipexole in Early Parkinson's Disease
000A99 Juliana Bronzova [Pays-Bas] ; Cristina Sampaio [Portugal] ; Robert A. Hauser [États-Unis] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Ad Theeuwes [Pays-Bas] ; Serge V. Van De Witte [Pays-Bas] ; Guus Van Scharrenburg [Pays-Bas]Double-Blind Study of Pardoprunox, a New Partial Dopamine Agonist, in Early Parkinson's Disease
000C13 Santiago Perez-Lloret [France] ; Emmanuelle Bondon-Guitton [France] ; Olivier Rascol [France] ; Jean-Louis Montastruc [France]Adverse Drug Reactions to Dopamine Agonists: A Comparative Study in the French Pharmacovigilance Database
000D20 Luigi M. Romito [Italie] ; Maria Fiorella Contarino [Italie] ; Nicola Vanacore [Italie] ; Anna Rita Bentivoglio [Italie] ; Massimo Scerrati [Italie] ; Alberto Albanese [Italie]Replacement of Dopaminergic Medication with Subthalamic Nucleus Stimulation in Parkinson's Disease : Long-Term Observation
000F08 Vincenzo Rizzo [Italie] ; Irene Arico [Italie] ; Claudia Mastroeni [Italie] ; Francesca Morgante [Italie] ; Giovanna Liotta [Italie] ; Paolo Girlanda [Italie] ; Rosalia Silvestri [Italie] ; Angelo Quartarone [Italie]Dopamine Agonists Restore Cortical Plasticity in Patients with Idiopathic Restless Legs Syndrome
000F09 Akiyuki Uzawa [Japon] ; Masahiro Mori [Japon] ; Shigeyuki Kojima [Japon] ; Satsuki Mitsuma [Japon] ; Yukari Sekiguchi [Japon] ; Toshihide Kanesaka [Japon] ; Satoshi Kuwabara [Japon]Dopamine Agonist-induced Antecollis in Parkinson's Disease
000F58 Frank Andersohn [Allemagne] ; Edeltraut Garbe [Allemagne]Cardiac and Noncardiac Fibrotic Reactions Caused by Ergot-and Nonergot-Derived Dopamine Agonists
000F60 Louis C. S. Tan [Singapour, États-Unis] ; Kenneth K. C. Ng [Singapour] ; Wing-Lok Au [Singapour, États-Unis] ; Raymond K. K. Lee [Singapour] ; Yiong-Huak Chan [Singapour] ; Nigel C. K. Tan [Singapour]Bromocriptine Use and the Risk of Valvular Heart Disease
000F85 Kelly E. Lyons [États-Unis] ; Rajesh Pahwa [États-Unis]An Open-Label Conversion Study of Pramipexole to Ropinirole Prolonged Release in Parkinson's Disease
001008 Connie Marras [Canada] ; Anthony E. Lang [Canada] ; Shirley W. Eberly [États-Unis] ; David Oakes [États-Unis] ; Stanley Fahn [États-Unis] ; Steven R. Schwid [États-Unis] ; Christopher Hyson [Canada] ; Ira Shoulson [États-Unis]A Comparison of Treatment Thresholds in Two Large Parkinson's Disease Clinical Trial Cohorts
001034 Fabrizio Stocchi [Italie] ; Michele Tagliati [États-Unis] ; C. Warren Olanow [États-Unis]Treatment of Levodopa-Induced Motor Complications
001063 Kazuo Yamashiro [Japon] ; Miki Komine-Kobayashi [Japon] ; Taku Hatano [Japon] ; Takao Urabe [Japon] ; Hideki Mochizuki [Japon] ; Nobutaka Hattori [Japon] ; Yoshitaka Iwama [Japon] ; Hiroyuki Daida [Japon] ; Michi Sakai [Japon] ; Takeo Nakayama [Japon] ; Yoshikuni Mizuno [Japon]The Frequency of Cardiac Valvular Regurgitation in Parkinson's Disease
001125 Peter Jenner [Royaume-Uni]Preventing and Controlling Dyskinesia in Parkinson's Disease : A View of Current Knowledge and Future Opportunities
001197 Nir Giladi [Israël]Medical Treatment of Freezing of Gait
001206 Eugenia Mamikonyan [États-Unis] ; Andrew D. Siderowf [États-Unis] ; John E. Duda [États-Unis] ; Marc N. Potenza [États-Unis] ; Stacy Horn [États-Unis] ; Matthew B. Stem [États-Unis] ; Daniel Weintraub [États-Unis]Long-Term Follow-Up of Impulse Control Disorders in Parkinson's Disease
001407 Susann Junghanns [Allemagne] ; Joerg T. Fuhrmann [Allemagne] ; Gregor Simonis [Allemagne] ; Christian Oelwein [Allemagne] ; Rainer Koch [Allemagne] ; Ruth H. Strasser [Allemagne] ; Heinz Reichmann [Allemagne] ; Alexander Storch [Allemagne]Valvular heart disease in parkinson's disease patients treated with dopamine agonists : A reader-blinded monocenter echocardiography study
001443 Paolo Barone [Italie] ; Janice Lamb [Royaume-Uni] ; Amanda Ellis [Royaume-Uni] ; Zoe Clarke [Royaume-Uni]Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease
001454 Wolfgang H. Oertel [Allemagne] ; Claudia Trenkwalder [Allemagne] ; Marco Zucconi [Italie] ; Heike Benes [Allemagne] ; Diego Garcia Borreguero [Espagne] ; Claudio Bassetti [Suisse] ; Markku Partinen [Finlande] ; Luigi Ferini-Strambi [Italie] ; Karin Stiasny-Kolster [Allemagne]State of the Art in Restless Legs Syndrome Therapy : Practice Recommendations for Treating Restless Legs Syndrome
001477 Nir Giladi [Israël] ; Babak Boroojerdi [Allemagne] ; Amos D. Korczyn [Israël] ; David J. Burn [Royaume-Uni] ; Carl E. Clarke [Royaume-Uni] ; Anthony H. V. Schapira [Royaume-Uni]Rotigotine Transdermal Patch in Early Parkinson's Disease : A Randomized, Double-Blind, Controlled Study Versus Placebo and Ropinirole
001592 Gregor Simonis [Allemagne] ; Joerg T. Fuhrmann [Allemagne] ; Ruth H. Strasser [Allemagne]Meta-analysis of heart valve abnormalities in parkinson's disease patients treated with dopamine agonists
001634 Claudio Lucetti [Italie] ; Paulo Del Dotto [Italie] ; Gianna Gambaccini [Italie] ; Roberto Ceravolo [Italie] ; Chiara Logi [Italie] ; Caterina Berti [Italie] ; Giuseppe Rossi [Italie] ; Maria Cristina Bianchi [Italie] ; Michela Tosetti [Italie] ; Luigi Murri [Italie] ; Ubaldo Bonuccelli [Italie]Influences of Dopaminergic Treatment on Motor Cortex in Parkinson Disease : A MRI/MRS Study
001666 Anthony H. V. Schapira [Royaume-Uni]Future Directions in the Treatment of Parkinson's Disease
001688 Wolfgang H. Oertel [Allemagne] ; Karin Stiasny-Kolster [Allemagne] ; Bettina Bergtholdt [Allemagne] ; Yngve Hallström [Suède] ; Jaan Albo [Suède] ; Lena Leissner [Suède] ; Thomas Schindler [Allemagne] ; Juergen Koester [Allemagne] ; Juergen Reess [Allemagne]Efficacy of pramipexole in restless legs syndrome : A six-week, multicenter, randomized, double-blind study (effect-RLS study)
001829 Carlos Singer [États-Unis] ; Janice Lamb [Royaume-Uni] ; Amanda Ellis [Royaume-Uni] ; Gary Layton [Royaume-Uni]A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease
001846 Cecilia Peralta [Autriche] ; Elisabeth Wolf [Autriche] ; Hannes Alber [Autriche] ; Klaus Seppi [Autriche] ; Silvana Müller [Autriche] ; Sylvia Bosch [Autriche] ; Gregor K. Wenning [Autriche] ; Otmar Pachinger [Autriche] ; Werner Poewe [Autriche]Valvular heart disease in Parkinson's disease vs. Controls : An echocardiographic study
001847 Ji-Youn Kim [Corée du Sud] ; EUN JOO CHUNG [Corée du Sud] ; SEUNG WOO PARK [Corée du Sud] ; WON YONG LEE [Corée du Sud]Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists
001869 Alexandre Castro-Caldas [Portugal] ; Paul Delwaide [Belgique] ; Wolfgang Jost [Allemagne] ; Marcelo Merello [Argentine] ; Adrian Williams [Royaume-Uni] ; Paolo Lamberti [Italie] ; Miguel Aguilar [Espagne] ; Susanna Del Signore [France] ; Pierre Cesaro [France]The parkinson-control study : A 1-year randomized, double- blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in parkinson's disease
001945 Katherine A. Grosset [Royaume-Uni] ; Graeme Macphee [Royaume-Uni] ; Guru Pal [Royaume-Uni] ; David Stewart [Royaume-Uni] ; Andrew Watt [Royaume-Uni] ; Jim Davie [Royaume-Uni] ; D. G. Grosset [Royaume-Uni]Problematic gambling on dopamine agonists : Not such a rarity
001B24 Daniel Oved [Israël] ; Ilan Ziv [Israël] ; Therese A. Treves [Israël] ; Diana Paleacu [Israël] ; Eldad Melamed [Israël] ; Ruth Djaldetti [Israël]Effect of dopamine agonists on fatigue and somnolence in Parkinson's disease
001B65 Claudia Trenkwalder [Allemagne] ; Karin Stiasny-Kolster [Allemagne] ; Andreas Kupsch [Allemagne] ; Wolfgang H. Oertel [Allemagne] ; Juergen Koester [Allemagne] ; Juergen Reess [Allemagne]Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome
001B69 Melissa J. Nirenberg [États-Unis] ; Cheryl Waters [États-Unis]Compulsive eating and weight gain related to dopamine agonist use
001D23 Katherine L. Widnell [États-Unis] ; Cynthia Comella [États-Unis]Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations
001E53 Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal]Evidence-based medical review update : Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004
001F83 Katherine Grosset [Royaume-Uni] ; Fiona Needleman [Royaume-Uni] ; Graeme Macphee [Royaume-Uni] ; Donald Grosset [Royaume-Uni]Switching from ergot to nonergot dopamine agonists in Parkinson's disease: A clinical series and five-drug dose conversion table
002001 Judit Horvath [Suisse] ; Robin D. Fross [États-Unis] ; Galit Kleiner-Fisman [Canada] ; René Lerch [Suisse] ; Hans Stalder [Suisse] ; Suzanne Liaudat [Suisse] ; William J. Raskoff [États-Unis] ; Keith D. Flachsbart [États-Unis] ; Harry Rakowski [Canada] ; Jean-Claude Pache [Suisse] ; Pierre R. Burkhard [Suisse] ; Anthony E. Lang [Canada]Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists
002034 Andrew H. Evans [Royaume-Uni] ; Regina Katzenschlager [Royaume-Uni] ; Dominic Paviour [Royaume-Uni] ; John D. O'Sullivan [Australie] ; Silke Appel [Royaume-Uni] ; Andrew D. Lawrence [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni]Punding in Parkinson's disease: Its relation to the dopamine dysregulation syndrome
002061 Karin Stiasny-Kolster [Allemagne] ; Ralf Kohnen [Allemagne] ; Erwin Schollmayer [Allemagne] ; J. Carsten Möller [Allemagne] ; Wolfgang H. Oertel [Allemagne]Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of Restless Legs Syndrome: A double-blind, placebo-controlled pilot study
002234 Marlene Jimenez Del Rio [Colombie] ; Sonia Moreno [Colombie] ; Gloria Garcia-Ospina [Colombie] ; Omar Buritica [Colombie] ; Carlos S. Uribe [Colombie] ; Francisco Lopera [Colombie] ; Carlos Velez-Pardo [Colombie]Autosomal recessive juvenile parkinsonism Cys212Tyr mutation in arkin renders lymphocytes susceptible to dopamine- and iron-mediated apoptosis
002257 Susan Hollan [Hongrie] ; Laszlo Vecsei [Hongrie] ; D. Kalman Magyar [Hongrie]Adverse effects of dopamine potentiation by long-term treatment with selegiline
002422 David R. Lynch [États-Unis] ; P. David Mozley [États-Unis] ; Set Sokol [États-Unis] ; Nicole M. C. Maas [États-Unis] ; Laura J. Balcer [États-Unis] ; Andrew D. Siderowf [États-Unis]Lack of effect of polymorphisms in dopamine metabolism related genes on imaging of TRODAT-1 in striatum of asymptomatic volunteers and patients with Parkinson's disease
002666 Giulio Cicarelli [Italie] ; Maria Teresa Pellecchia [Italie] ; Giuseppe De Michele [Italie] ; Gilberto Pizzolato [Italie] ; Paolo Barone [Italie]Paradoxical response to apomorphine in a case of atypical parkinsonism
002708 Petr Kanovsky [République tchèque] ; Dagmar Kubova [République tchèque] ; Martin Bares [République tchèque] ; Hana Hortova [République tchèque] ; Hana Streitova [République tchèque] ; Ivan Rektor [République tchèque] ; Vladimir Znojil [République tchèque]Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: Results of a two-year, prospective follow-up
002765 J. Carsten Moller [Allemagne] ; Karin Stiasny [Allemagne] ; Volker Hargutt [Allemagne] ; Werner Cassel [Allemagne] ; Heiko Tietze [Allemagne] ; J. Hermann Peter [Allemagne] ; H.-Peter Krüger [Allemagne] ; Wolfgang H. Oertel [Allemagne]Evaluation of sleep and driving performance in six patients with Parkinson's disease reporting sudden onset of sleep under dopaminergic medication: A pilot study
002777 Guillermo Paradiso [Canada] ; Farooq Khan [Canada] ; Robert Chen [Canada]Effects of apomorphine on flexor reflex and periodic limb movement
002808 DA agonists: ergot derivatives: Bromocriptine
002809 DA agonists: Non-Ergot derivatives: Ropinirole
002810 DA agonists: Non-Ergot derivatives: Pramipexole
002811 DA agonists: Non-Ergot derivatives: Piribedil
002812 DA agonists: Non-Ergot derivatives: Apomorphine
002813 DA agonists: Ergot derivatives: Pergolide
002814 DA agonists: Ergot derivatives: Lisuride
002815 DA agonists: Ergot derivatives: Dihydroergocryptine (DHEC)
002816 DA agonists: Ergot derivatives: Cabergoline
002858 Alice J. Manson [Royaume-Uni] ; Kirsten Turner [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni]Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long-term follow-up study of 64 patients
002863 Amantadine and other antiglutamate agents
002919 William Koller [États-Unis] ; Andrew Lees (neurologue) [Royaume-Uni] ; Miroslava Doder [Royaume-Uni] ; Mariese Hely [Australie]Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations
002930 Virgilio Gerald H. Evidente [Philippines]Piribedil for restless legs syndrome: A pilot study
002966 Fabrizio Stocchi [Italie] ; Laura Vacca [Italie] ; Alfredo Berardelli [Italie] ; Francesca De Pandis [Italie] ; Stefano Ruggieri [Italie]Long-duration effect and the postsynaptic compartment : Study using a dopamine agonist with a short half-life
002A28 Alberto Albanese [Italie] ; Ubaldo Bonuccelli [Italie] ; Christine Brefel [France] ; K. Ray Chaudhuri [Royaume-Uni] ; Carlo Colosimo [Italie] ; Tobias Eichhorn [Allemagne] ; Eldad Melamed [Israël] ; Pierre Pollak [France] ; Teus Van Laar [Pays-Bas] ; Mario Zappia [Italie]Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease
002A78 C. W. Olanow [États-Unis] ; A. H. V. Schapira [Royaume-Uni] ; T. Roth [États-Unis]Waking up to sleep episodes in Parkinson's disease
002B03 C. Ramaker [Pays-Bas] ; W. J. T. Van De Beek [Pays-Bas] ; M. J. J. Finken [Pays-Bas] ; B. J. J. Van Hilten [Pays-Bas]The efficacy and safety of adjunct bromocriptine therapy for levodopa-induced motor complications : A systematic review
002B13 S. A. Factor [États-Unis] ; D. L. Brown [États-Unis] ; E. S. Molho [États-Unis]Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson's disease
002B69 Robert A. Hauser [États-Unis] ; Mervat N. Wahba [États-Unis] ; Theresa A. Zesiewicz [États-Unis] ; W. Mcdowell Anderson [États-Unis]Modafinil treatment of pramipexole-associated somnolence
002C10 Sarah A. Treseder [Royaume-Uni] ; Lance A. Smith [Royaume-Uni] ; Peter Jenner [Royaume-Uni]Endogenous dopaminergic tone and dopamine agonist action
002C52 E. Luginger [Autriche] ; G. K. Wenning [Autriche] ; S. Bosch [Autriche] ; Werner Poewe [Autriche]Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's Disease
002C57 Werner Poewe [Autriche] ; Gregor K. Wenning [Autriche]Apomorphine : An underutilized therapy for Parkinson's disease
002C67 V. G. H. Evidente [États-Unis, Philippines] ; C. H. Adler [États-Unis] ; J. N. Caviness [États-Unis] ; J. G. Hentz [États-Unis] ; K. Gwinn-Hardy [États-Unis]Amantadine is beneficial in restless legs syndrome
002C98 S. A. Factor [États-Unis] ; E. S. Molho [États-Unis]Transient benefit of amantadine in Parkinson's disease : The facts about the myth
002D27 W. Ondo [États-Unis] ; MD [États-Unis]Ropinirole for restless legs syndrome
002D60 L. E. Davis [États-Unis] ; J. C. Adair [États-Unis]Parkinsonism from methanol poisoning : Benefit from treatment with anti-Parkinson drugs
002E11 M. Merello [Argentine] ; Andrew Lees (neurologue) [Royaume-Uni] ; J. Balej [Argentine] ; A. Cammarota [Argentine] ; R. Leiguarda [Argentine]GPi firing rate modification during beginning-of-dose motor deterioration following acute administration of apomorphine
002E24 Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated Parkinsonian patients
002E66 M. Merello [Argentine] ; J. Balej [Argentine] ; M. Delfino [Argentine] ; A. Cammarota [Argentine] ; O. Betti [Argentine] ; R. Leiguarda [Argentine]Apomorphine induces changes in GPi spontaneous outflow in patients with Parkinson's disease
003085 P. J. Blanchet [États-Unis] ; S. Konitsiotis [États-Unis] ; T. N. Chase [États-Unis]Amantadine reduces levodopa-induced dyskinesias in Parkinsonian monkeys
003397 G. Geminiani [Italie] ; V. Fetoni [Italie] ; S. Genitrini [Italie] ; P. Giovannini [Italie] ; F. Tamma [Italie] ; T. Caraceni [Italie]Cabergoline in Parkinson's disease complicated by motor fluctuations
003564 R. J. Vermeulen [Pays-Bas] ; B. Drukarch [Pays-Bas] ; M. C. R. Sahadat ; C. Goosen ; E. C. Wolters [Pays-Bas] ; J. C. Stoof [Pays-Bas]The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys
003662 D. Bravi [États-Unis] ; T. L. Davis ; M. M. Mouradian ; T. N. ChaseTreatment of Parkinson's disease with the partial dopamine agonist EMD 49980
003800 J.-F. De Saint Victor [France] ; C.-L. GervasonLevopoda-induced diphasic dyskinesias improved by subcutaneous apomorphine
003807 S. Przedborski [Belgique] ; A. Liard ; J. HildebrandInduction of mania by apomorphine in a depressed Parkinsonian patient
003818 M. Emre [Suisse] ; U. K. Rinne ; A. Rascol ; A. Lees ; Yves Agid [France] ; X. LatasteEffects of a selective partial D1 agonist, CY 208-243, in De Novo patients with Parkinson disease
003820 D. Bravi [États-Unis] ; J. J. Anderson ; F. Dagani ; T. L. Davis ; R. Feerari ; M. Gillespie ; T. N. ChaseEffect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease
003821 B. Gomez-Mancilla [Canada] ; R. Boucher ; P. J. BedardEffect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of Parkinsonism
003904 S. T. Gancher ; J. G. Nutt ; W. R. WoodwardAbsorption of apomorphine by various routes in parkinsonism
003920 J. M. Cedarbaum ; M. Clark ; L. H. Toy ; A. Green-ParsonsSustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease : evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation
003936 M. E. Rodriguez ; M. R. Luquin ; G. Lera ; G. Delgado ; J. M. Salazar ; J. A. ObesoNeuroleptic malignant syndrome treated with subcutaneous lisuride infusion
003943 S. Boyce ; C. E. Clarke ; R. Luquin ; D. Peggs ; R. G. Robertson ; I. J. Mitchell ; M. A. Sambrook ; A. R. CrossmanInduction of chorea and dystonia in parkinsonian primates
003966 Werner Poewe [Autriche] ; G. Luef ; B. Kleedorfer ; M. EmreAntiparkinsonian activity of a non-ergot dopamine agonist, CV 205-502, in patients with fluctuating Parkinson's disease
003972 A. R. CrossmanA hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment
003986 R. J. Coleman ; K. W. Lange ; N. P. Quinn ; A. E. Loper ; J. V. Bondi ; M. Hitchens ; S. M. Stahl ; C. D. MarsdenThe antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+ PHNO): preliminary results
003997 P. A. Kempster ; Andrew Lees (neurologue) [Royaume-Uni] ; P. Crichton ; J. P. Fkankel ; P. ShorvonOff-period belching due to a reversible disturbance of oesophageal motility in Parkinson's disease and its treatment with apomorphine
003A14 R. F. Pfeiffer ; L. H. Herrera ; C. S. Glaeske ; R. E. HofmanCQP A01-403 in Parkinson's disease: an open-label pilot study
003A18 J. A. Temlett ; N. P. Quinn ; P. G. Jenner ; C. D. Marsden ; E. Pourcher ; A.-M. Bonnet ; Y. Acid ; R. Markstein ; X. LatasteAntiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease
003A68 J. G. De Yebenes ; S. Fahn ; V. Jackson-Lewis ; M.-A. MenaThe effect of intracerebroventricular infusion of (+)-4-propyl-9-hydroxynapthoxacine (PHNO) through a totally implanted drug delivery system in rats with dopamine deficiency
003A90 J. G. De Yebenes ; S. Fahn ; S. Lovelle ; V. Jackson-Lewis ; P. Jorge ; M. A. Mena ; J. Reiriz ; J. C. Bustos ; C. Magarinos ; A. MartinezContinuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease
003A96 F. Grandas ; N. Quinn ; P. Critchley ; A. Rohan ; C. D. Marsden ; S. M. StahlAntiparkinsonian activity of a single oral dose of PHNO
003A97 N. Nomoto ; S. Stahl ; P. Jenner ; C. D. MarsdenAntiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024